BMO Capital Reiterates a Buy on BioMarin Pharmaceutical (BMRN)

Group 1 - BioMarin Pharmaceutical Inc. is considered one of the best affordable biotech stocks to invest in, with a Buy rating and a price target of $115.00 set by BMO Capital analyst Kostas Biliouris [1] - The potential expansion of Palynziq into the adolescent market is a key reason for the optimistic rating, as it may significantly increase market share [2] - Palynziq has shown strong efficacy and safety in adolescents, with improved tolerability and significant reductions in blood Phe levels compared to adults [2] Group 2 - BioMarin has a robust base business, and the potential of other products like Voxzogo supports a positive outlook for the stock [3] - The company develops and commercializes therapies for serious and life-threatening medical conditions and rare diseases, with a product pipeline that includes Valoctocogene roxaparvovec, Vosoritide, and BMN 307 [3]